Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Australia
  4. Australian Stock Exchange
  5. Immutep Limited
  6. News
  7. Summary
    IMM   AU000000IMM6

IMMUTEP LIMITED

(IMM)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Immutep : Results of EGM

07/26/2021 | 04:58am EDT

26 July 2021

ASX Market Announcements Office

ASX Limited

20 Bridge Street SYDNEY NSW 2000

RESULTS OF EXTRAORDINARY GENERAL MEETING

Immutep Limited (ASX: IMM; NASDAQ: IMMP) advises that the details of the resolutions and the proxies received in respect of each resolution are set out in the attached proxy summary in accordance with ASX Listing Rule 3.13.2 and section 251AA of the Corporations Act 2001 (Cth).

All resolutions were passed and decided by way of poll.

This announcement was authorised for release by Deanne Miller, COO & Company Secretary of Immutep Limited.

Further information can be found on the Company's website www.immutep.comor by contacting:

Australian Investors/Media:

Catherine Strong, Citadel-MAGNUS

+61 (0)406 759 268; cstrong@citadelmagnus.com

U.S. Media:

Tim McCarthy, LifeSci Advisors

+1 (212) 915.2564; tim@lifesciadvisors.com

Immutep Limited, Level 12, 95 Pitt Street, Sydney NSW 2000 ABN: 90 009 237 889

Immutep Limited

Extraordinary General Meeting

Monday, 26 July 2021

Results of Meeting

The following information is provided in accordance with section 251AA(2) of the Corporations Act 2001 (Cth) and ASX Listing Rule 3.13.2.

Resolution details

Resolution

Resolution

Type

Resolution 1. Ratification of prior issue

of Tranche 1 Placement Shares under

Ordinary

ASX Listing Rule 7.1

Resolution 2. Ratification of prior issue

of Tranche 1 Placement Shares under

Ordinary

ASX Listing Rule 7.1A

Resolution 3. Approval for the issue of

Tranche 2 Placement Shares under

Ordinary

ASX Listing Rule 7.1

Instructions given to validly appointed proxies

(as at proxy close)

For

Against

Proxy's

Abstain

Discretion

194,624,947

2,549,359

2,848,292

37,524,542

97.30%

1.27%

1.42%

194,406,980

2,659,005

2,956,923

37,524,232

97.19%

1.33%

1.48%

197,021,777

2,884,568

2,900,222

34,740,573

97.15%

1.42%

1.43%

Number of votes cast on the poll

(where applicable)

For

Against

Abstain*

198,060,403

2,549,359

37,851,574

98.73%

1.27%

197,951,067

2,659,005

37,851,264

98.67%

1.33%

200,509,163

2,884,568

35,067,605

98.58%

1.42%

Resolution

Result

Carried /

Not Carried

Carried

Carried

Carried

* Votes cast by a person who abstains on an item are not counted in calculating the required majority on a poll.

Disclaimer

Immutep Ltd. published this content on 26 July 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 26 July 2021 08:57:04 UTC.


© Publicnow 2021
All news about IMMUTEP LIMITED
09/02IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients..
PU
09/01IMMUTEP : Completes Patient Enrollment in Stage 2 of Part B of NSCLC Study; Shar..
MT
09/01IMMUTEP : PRELIMINARY FINAL REPORT (Form 6-K)
PU
09/01IMMUTEP : Completes Recruitment, Dosing in Phase 2 Trial of Non-Small Cell Lung ..
MT
09/01IMMUTEP : Completes Recruitment of 2nd line PD-1/PD-L1 refractory NSCLC Patients..
PU
08/31Immutep Limited Announces Recruitment of Patients Completed for Part B of TAC..
CI
08/31IMMUTEP : Chinese Partner, Eoc Pharma, Expands Efti Trial Pipeline
AQ
08/31IMMUTEP : Chinese Partner to Expand Clinical Trial Pipeline for Cancer Drug
MT
08/31IMMUTEP : S CHINESE PARTNER, EOC PHARMA, EXPANDS EFTI TRIAL PIPELINE (Form 6-K)
PU
08/30IMMUTEP : Partner, EOC Pharma, Expands Efti Trial Pipeline
PU
More news
Analyst Recommendations on IMMUTEP LIMITED
More recommendations
Financials
Sales 2022 8,86 M 6,44 M 6,44 M
Net income 2022 -31,3 M -22,8 M -22,8 M
Net Debt 2022 6,40 M 4,65 M 4,65 M
P/E ratio 2022 -11,9x
Yield 2022 -
Capitalization 451 M 328 M 328 M
EV / Sales 2022 51,6x
EV / Sales 2023 12,7x
Nbr of Employees -
Free-Float 85,2%
Chart IMMUTEP LIMITED
Duration : Period :
Immutep Limited Technical Analysis Chart | IMM | AU000000IMM6 | MarketScreener
Technical analysis trends IMMUTEP LIMITED
Short TermMid-TermLong Term
TrendsBullishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,53 AUD
Average target price 1,18 AUD
Spread / Average Target 122%
EPS Revisions
Managers and Directors
Marc Voigt Chief Executive Officer, CFO & Executive Director
David Fang Finance Director & Assistant Secretary
Russell John Howard Non-Executive Chairman
Frédéric Triebel Chief Scientific & Medical Officer
Deanne Miller COO, Co-Secretary & General Counsel
Sector and Competitors
1st jan.Capi. (M$)
IMMUTEP LIMITED27.71%328
MODERNA, INC.311.65%177 867
LONZA GROUP AG36.36%62 278
IQVIA HOLDINGS INC.43.07%49 407
CELLTRION, INC.-23.26%31 021
SEAGEN INC.-10.81%27 940